Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

black diamond therapeutics inc - BDTX

BDTX

Close Chg Chg %
2.16 0.10 4.40%

Closed Market

2.26

+0.10 (4.40%)

Volume: 711.10K

Last Updated:

Feb 6, 2026, 4:00 PM EDT

Trade Now

Company Overview: black diamond therapeutics inc - BDTX

BDTX Key Data

Open

$2.23

 Day Range

2.19 - 2.29

52 Week Range

1.20 - 4.94

 Market Cap

$136.17M

Shares Outstanding

56.97M

 Public Float

44.75M

Beta

3.37

 Rev. Per Employee

N/A

P/E Ratio

5.95

 EPS

$0.38

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

934.27K

  

BDTX Performance

1 Week
 
 -9.44%
 
1 Month
 
 -19.75%
 
3 Months
 
 -42.03%
 
1 Year
 
 -8.33%
 
5 Years
 
 -92.21%
 

BDTX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 9
Full Ratings ➔

About black diamond therapeutics inc - BDTX

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type-mediated toxicities, and be brain-penetrant to treat central nervous system diseases. It is currently focused on advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.

BDTX At a Glance

Black Diamond Therapeutics, Inc.
245 First Street
Cambridge, Massachusetts 02142
Phone 1-617-252-0848 Revenue 0.00
Industry Biotechnology Net Income -69,676,000.00
Sector Health Technology Employees 24
Fiscal Year-end 12 / 2025
View SEC Filings

BDTX Valuation

P/E Current 5.954
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 1.455
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -0.548
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.536

BDTX Efficiency

Revenue/Employee N/A
Income Per Employee -2,903,166.667
Receivables Turnover N/A
Total Asset Turnover N/A

BDTX Liquidity

Current Ratio 4.918
Quick Ratio 4.918
Cash Ratio 4.791

BDTX Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -49.555
Return on Equity -69.669
Return on Total Capital -66.062
Return on Invested Capital -57.825

BDTX Capital Structure

Total Debt to Total Equity 26.639
Total Debt to Total Capital 21.035
Total Debt to Total Assets 18.09
Long-Term Debt to Equity 22.551
Long-Term Debt to Total Capital 17.808
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Black Diamond Therapeutics Inc - BDTX

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
2.22M 3.24M 437.00K 343.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.22M 3.24M 437.00K 343.00K
Depreciation
2.22M 3.24M 437.00K 343.00K
Amortization of Intangibles
- - - -
-
COGS Growth
+269.50% +46.05% -86.50% -21.51%
Gross Income
(2.22M) (3.24M) (437.00K) (343.00K)
Gross Income Growth
-269.50% -46.05% +86.50% +21.51%
Gross Profit Margin
- - - -
-
2021 2022 2023 2024 5-year trend
SG&A Expense
124.66M 89.59M 86.02M 75.49M
Research & Development
94.61M 61.20M 58.91M 50.97M
Other SG&A
30.04M 28.39M 27.11M 24.52M
SGA Growth
+80.74% -28.13% -3.98% -12.24%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 2.94M
-
EBIT after Unusual Expense
(126.87M) (92.83M) (86.46M) (78.78M)
Non Operating Income/Expense
1.28M 1.66M 4.02M 9.11M
Non-Operating Interest Income
3.46M 2.03M 1.92M 2.18M
Equity in Earnings of Affiliates
- - - (2.25M)
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(125.60M) (91.17M) (82.44M) (69.68M)
Pretax Income Growth
-86.75% +27.41% +9.57% +15.48%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - (2.25M)
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(125.60M) (91.17M) (82.44M) (69.68M)
Minority Interest Expense
- - - -
-
Net Income
(125.60M) (91.17M) (82.44M) (69.68M)
Net Income Growth
-86.75% +27.41% +9.57% +15.48%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(125.60M) (91.17M) (82.44M) (69.68M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(125.60M) (91.17M) (82.44M) (69.68M)
EPS (Basic)
-3.4706 -2.5098 -1.8756 -1.2662
EPS (Basic) Growth
-69.81% +27.68% +25.27% +32.49%
Basic Shares Outstanding
36.19M 36.33M 43.95M 55.03M
EPS (Diluted)
-3.4706 -2.5098 -1.8756 -1.2662
EPS (Diluted) Growth
-69.81% +27.68% +25.27% +32.49%
Diluted Shares Outstanding
36.19M 36.33M 43.95M 55.03M
EBITDA
(124.66M) (89.59M) (86.02M) (75.49M)
EBITDA Growth
-80.74% +28.13% +3.98% +12.24%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 9.429
Number of Ratings 9 Current Quarters Estimate -0.029
FY Report Date 03 / 2026 Current Year's Estimate -0.63
Last Quarter’s Earnings -0.19 Median PE on CY Estimate N/A
Year Ago Earnings 0.446 Next Fiscal Year Estimate -0.884
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 8 8 9 8
Mean Estimate -0.03 -0.19 -0.63 -0.88
High Estimates 1.03 -0.12 -0.19 -0.50
Low Estimate -0.25 -0.33 -0.90 -1.34
Coefficient of Variance -1,464.85 -38.93 -34.99 -36.24

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 7 7 8
OVERWEIGHT 1 1 1
HOLD 1 1 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Black Diamond Therapeutics Inc - BDTX

Date Name Shares Transaction Value
Mar 24, 2025 Ali Behbahani Director 70,980 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $1.88 per share 133,442.40
Mar 24, 2025 Prakash Raman Director 16,993 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $1.88 per share 31,946.84
Mar 21, 2025 Bellevue Asset Management AG 7,517,839 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $2.07 per share 15,561,926.73
Mar 21, 2025 Bellevue Asset Management AG 7,217,839 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1.94 per share 14,002,607.66
Mar 21, 2025 Bellevue Asset Management AG 6,217,839 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $2.31 per share 14,363,208.09
Mar 21, 2025 Bellevue Asset Management AG 4,217,839 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $2 per share 8,435,678.00
Mar 21, 2025 Bellevue Asset Management AG 3,817,839 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $2.09 per share 7,979,283.51
Mar 21, 2025 Bellevue Asset Management AG 3,233,547 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1.95 per share 6,305,416.65
Mar 21, 2025 Bellevue Asset Management AG 2,733,547 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $2.12 per share 5,795,119.64

Black Diamond Therapeutics Inc in the News